Glaukos Q2 sales jump 50%; raises net sales forecast

Glaukos

29/07/2026 21:17

Overview
Ophthalmic pharma and device firm's Q2 sales rose 50% yr/yr, beating analyst expectations
Adjusted net loss for Q2 narrowed and beat analyst expectations

Outlook
Glaukos raises 2026 net sales guidance to $680 mln-$700 mln from $620 mln-$635 mln
Company expects strong growth momentum driven by iDose TR and Epioxa

Result Drivers
PRODUCT LAUNCHES - Co said record results were driven by commercial execution of iDose TR and Epioxa
U.S. GLAUCOMA SALES - U.S. glaucoma net sales rose 64% yr/yr, contributing to overall sales growth
PIPELINE INVESTMENT - Co continued to invest in development of novel, dropless platform technologies

Company press release: ID:nBw7z323Ga

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
Beat
$185.60 mln
$150.92 mln (14 Analysts)
Q2 Adjusted Net Loss
Beat
$8.30 mln
$12.33 mln (13 Analysts)
Q2 Net Loss
 
$18.40 mln
 
Q2 Gross Margin
 
82%
 
Q2 Adjusted Gross Margin
 
85%
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Glaukos Corp is $166.50, about 10% above its July 28 closing price of $151.33

Reuters Recommended Reads
July 29 - Bausch + Lomb Q2 revenue beats on surgical segment growth; lifts outlook
July 29 - Boston Scientific trims annual profit forecast on softer Watchman device demand
July 29 - GE HealthCare tops quarterly estimates, weighs patient care unit sale

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)